Rhea Raghu

Ms. Rhea Raghu

N/A
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KLKristen Lospinoso
Kristen Lospinoso
MDMikhail G. Dozmorov
Mikhail G. Dozmorov
NFNadine El Fawal
Nadine El Fawal
RRRhea Raghu
Rhea Raghu
WCWook-Jin Chae
Wook-Jin Chae
ELEun Lee
Eun Lee
The genes involved in implantation and placentation are tightly regulated to ensure a healthy pregnancy. The endoplasmic reticulum aminopeptidase 2 (ERAP2) gene is associated with preeclampsia (PE). Our studies have determined that an isoform of ERAP2-arginine (N), expressed in trophoblast cells (TC), significantly activates immune cells, and ERAP2N-expressing TCs are preferentially killed by both cytotoxic T lymphocytes (CTLs) and Natural Killer cells (NKCs). To understand the cause of this phenomenon, we surveyed differentially expressed genes (DEGs) between ERAP2N expressing and non-expressing TCs. Our RNAseq data revealed 581 total DEGs between the two groups. 289 genes were up-regulated, and 292 genes were down-regulated. Interestingly, most of the down-regulated genes of significance were pro-survival genes that play a crucial role in cell survival (LDHA, EGLN1, HLA-C, ITGB5, WNT7A, FN1). However, the down-regulation of these genes in ERAP2N-expressing TCs translates into a propensity for cell death. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that 64 DEGs were significantly enriched in nine pathways, including “Protein processing in endoplasmic reticulum” and “Antigen processing and presentation”, suggesting that the genes may be associated with peptide processes involved in immune recognition during the reproductive cycle.

9 January 2026 in Toxicology Reports
Verified
Journal Article
Open access
KLKaren Lin
Karen Lin
YSYehao Sun
Yehao Sun
RRRhea Raghu
Rhea Raghu
PSParth Suharu
Parth Suharu
Felix EffahFelix Effah
Felix Effah
Irfan RahmanIrfan Rahman
Irfan Rahman
Hemp-derived cannabinoids (CBDs) such as Δ8- and Δ10-tetrahydrocannabinol (THC) in cannabis e-cigarettes have been growing in popularity among youth, causing great concern for their health effects. Previous novel lung injury outbreaks, such as E-cigarette or Vaping Use-Associated Lung Injury (EVALI), were associated with the rising use of e-cigarettes and vaping products. Toxicological studies have revealed that chronic exposure to cannabis vapor can cause adverse brain and pulmonary effects. Hemp products are classified as cannabis and set a limit of no more than 0.3 % Δ9-THC, while products containing more than 0.3 % are defined as ‘marijuana.’ This has led to the proliferation of hemp-derived intoxicating cannabinoids, such as Δ8- and Δ10-THC, in addition to cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), and Δ9-THC appearing in combination products. CBD frequently serves as a significant component of hemp-derived formulations, making it a central consideration for toxicological and regulatory evaluation as well. This phenomenon poses significant health risks to youth because these newer THC isomers and products are currently unregulated and not well-researched, yet they are still widely available. Therefore, we have examined the pharmacology, toxicity, potential therapeutic uses and possible health risks of several THC and hemp-derived cannabinoids. This review draws insightful highlights to the public health consequences of secondary exposures to CBD and THC, and their molecular mechanisms of action. It underscores the urgency for a regulatory oversight over unregulated cannabinoid markets to prevent toxicity of vaping-related health crises and other rapidly emerging cannabis health disorders, like the cannabinoid hyperemesis syndrome (CHS).

21 February 2023 in Placenta
Verified
Journal Article
Open access
RRRhea Raghu
Rhea Raghu
LKLesia Kurlak
Lesia Kurlak
ELEun Lee
Eun Lee
HMHiten D Mistry
Hiten D Mistry
Endoplasmic reticulum resident protein 44 (ERp44) is a zinc-metalloprotein, regulating Endoplasmic reticulum aminopeptidase 1 (ERAP1) and Angiotensin II (Ang II). We explored placental ERp44 expression and components of the renin-angiotensin-system (RAS) in pre-eclampsia (PE), correlating these to ERAP1 expression and placental zinc concentrations. Placental tissue, taken at time of delivery in normotensive women or women with PE (n = 12/group), were analysed for ERp44, AT1R, AT2R and AT4R by qPCR. Protein ERp44 expression was measured by immunohistochemistry and compared to previously measured ERAP1 expression. Placental zinc was measured by inductively-coupled-mass-spectrometry. ERp44 gene/protein expression were increased in PE (P < 0.05). AT1R expression was increased (P = 0.02) but AT4R decreased (P = 0.01) in PE, compared to normotensive controls. A positive association between ERp44 and AT2R expression was observed in all groups. ERp44 was negatively correlated with ERAP1 protein expression in all samples. Placental zinc concentrations were lower in women with PE (P = 0.001) and negatively associated with ERp44 gene expression. Increased placental ERp44 could further reduce ERAP1 release in PE, potentially preventing release of Ang IV and thus lowering levels of Ang IV which consequently diminishes the possibility of counterbalancing the activity of vasoconstrictive, Ang II. The lower placental zinc may contribute to dysfunction of the ERp44/ERAP1 complex, exacerbating the hypertension in PE.

31 January 2026 in Toxicology
Verified
Journal Article
Closed access
FEFelix Effah
Felix Effah
MSMohana Sengupta
Mohana Sengupta
YSYehao Sun
Yehao Sun
IFImam Faizan
Imam Faizan
GKGagandeep Kaur
Gagandeep Kaur
Irfan RahmanIrfan Rahman
Irfan Rahman

12 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KLKaren Lin
Karen Lin
YSYehao Sun
Yehao Sun
RRRhea Raghu
Rhea Raghu
PSParth Suharu
Parth Suharu
FEFelix Effah
Felix Effah
Irfan RahmanIrfan Rahman
Irfan Rahman
Hemp-derived cannabinoids (CBDs) such as Δ8- and Δ10-tetrahydrocannabinol (THC) in cannabis e-cigarettes have been growing in popularity among youth, causing a great concern for their health effects. Previous novel lung injury outbreaks, namely E-cigarette or Vaping Use-Associated Lung Injury (EVALI), were associated with the rising use of e-cigarettes and vaping products. Toxicological studies have revealed that chronic exposure to cannabis vapor can cause adverse brain and pulmonary effects. Federal regulatory policies like the United States 2018 Farm Bill classify hemp as cannabis and set a limit of no more than 0.3% Δ9-THC, while products containing more than 0.3% are defined as ‘marijuana.’ This regulatory loophole has led to the proliferation of hemp-derived intoxicating cannabinoids, such as Δ8- and Δ10-THC, in addition to cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG) and Δ9-THC appearing in combination products on the market. This phenomenon poses significant health risks to youth because these newer THC isomers and products are currently unregulated and not well-researched, yet they are still widely available. Therefore, we have examined the potential therapeutical uses, toxicity, pharmacology, and possible health risks of several THC and hemp-derived cannabinoids. This review also draws insightful highlights to the public health consequences of secondary exposures to CBD and THC, and their molecular mechanisms of actions. It underscores the urgency for a strict regulatory oversight over unregulated cannabinoid markets to prevent other vaping-related health crises and other rapidly emerging cannabis health disorders, like the cannabinoid hyperemesis syndrome (CHS).